[Pe-021] English Poster Session 021

[Pe-021-3] Efficacy and Safety of Inebilizumab as Treatment for Newly Presenting NMOSD [Encore Presentation]

Dewei She¹, John W. Lindsey², Evanthia Bernitsas³, Naruyasu Komorita⁴, Bruce A C. Cree⁵ (1.Horizon Therapeutics, USA, 2.Division of Multiple Sclerosis and Neuroimmunology, University of Texas Health Science Center at Houston, USA, 3.Multiple Sclerosis Center, Wayne State School of Medicine, USA, 4.Mitsubishi Tanabe Pharma Corporation, Japan, 5.UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, USA)